ESR1 and breast cancer: Currently, CFI-402257 is under clinical investigation in breast cancer (Table 3), in combination with Fulvestrant, as part of a trial evaluating its efficacy in patients with advanced ER+/HER2− breast cancer who have previously received CDK4/6i and endocrine therapy (NCT05251714).